Anesthesia · Neuromuscular BlockadeRegulatory Approvalcompetitivenear-term

FDA Grants Approval for Sugammadex Sodium ANDA214319 by Sun Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 6:30:48 AM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Sugammadex Sodium by Sun Pharma introduces a new competitor in the neuromuscular blockade reversal market. This development necessitates a reassessment of pricing and market strategies for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Sun Pharma's entry on market dynamics and pricing strategies for Sugammadex alternatives. The strongest clinical anchor is Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In nmus rehab, 8 regulatory and 1 competitive items passed relevance filtering for Sun Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Sugammadex Sodium under ANDA214368 (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex). This approval allows Sun Pharma to enter the market for Sugammadex, potentially increasing competition in the neuromuscular blockade reversal space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (sugammadex); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for other products.

Key Opportunities

Sun Pharma's entry may disrupt current market dynamics, potentially affecting revenue and market share for existing Sugammadex alternatives.
Portfolio teams should assess the impact of Sun Pharma's entry on market dynamics and pricing strategies for Sugammadex alternatives.

What Would Change This Assessment

This becomes more urgent if Monitor market launch timelines and any subsequent competitive responses from other manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
Outcome from FDA Grants Approval for Sugammadex Sodium under ANDA214368 would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Approval for Sugammadex Sodium under ANDA214368
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex)
FDA Approves Sugammadex Sodium for Gland Pharma
Humanexa Signalslow relevance
Entity match (sugammadex)
FDA grants priority review for NUPLAZID supplemental application
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sun Pharma
Sugammadex

Commercial impact

medium

Sun Pharma's entry may disrupt current market dynamics, potentially affecting revenue and market share for existing Sugammadex alternatives.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for other products.

What to watch

Monitor market launch timelines and any subsequent competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.